SmithKline Beecham Requip for Parkinson's study shows 24% improvement in motor functioning.
Executive Summary
SMITHKLINE REQUIP FOR PARKINSON's IMPROVES MOTOR FUNCTION 24% compared to a 3% decline on placebo, according to results from one of three Phase III studies of ropinirole presented at the American Academy of Neurology meeting in San Francisco March 26. The 24% improvement was statistically significant compared to placebo-treated patients with Parkinson's disease who had no or little exposure to dopaminergic anti-Parkinson therapy.